<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gordon, Debra</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Tannock, Lisa</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">New-Onset Diabetes after Transplantation</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">33-34</style></pages><abstract><style  face="normal" font="default" size="100%">New-onset diabetes after transplantation (NODAT) is recognized as one of the major medical complications of solid-organ transplantation. A spectrum of problems is attributed to NODAT, including impaired graft function, infectious complications, patient inconvenience, and increased costs, as well as patient mortality [Woodward RS et al. Am J Transplant 2003].</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>